Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Intravenous formulation and LC/MS/MS analysis method for GMC1
US10010534B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10010534-B2 |
| Application number | US-201715471102-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 28, 2017 |
| Priority date | Mar 29, 2016 |
| Publication date | Jul 3, 2018 |
| Grant date | Jul 3, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.
First claim
Opening claim text (preview).
The invention claimed is: 1. A co-solvent formulation comprising (i) 20 to 80% PEG 300, (ii) 20 to 80% caprylocaproyl polyoxyl-8 glycerides and (iii) 1 to 200 mg/mL GMC1, wherein GMC1 has a formula of: 2. The co-solvent formulation of claim 1 , wherein the formulation comprises (i) 50% PEG 300, (ii) 50% caprylocaproyl polyoxyl-8 glycerides and (iii) 10 mg/mL GMC1. 3. A method of treating prostate cancer comprising administering to a subject having prostate cancer a formulation comprising (i) 20% to 80% PEG 300, (ii) 20% to 80% caprylocaproyl polyoxyl-8 glycerides and (iii) 1 to 200 mg/mL GMC1, wherein GMC1 has a formula of: 4. The method of claim 3 , further comprising administering chemotherapy or radiation treatments.
Assignees
Inventors
Classifications
of liquid biological material · CPC title
Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title
Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10010534B2 cover?
- Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.
- Who is the assignee on this patent?
- Cox Marc, Xie Huan, Ekpenyong Oscar, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4184. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).